Treating rheumatoid arthritis with DMARDs and biologics: Targeting disease compartments with approved and experimental agents

Drug Discovery World

Volumn 9, Issue 4, 2008, Pages 15-20

  Fogler, William E ^a  

^a ENTREMED INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ABATACEPT; ADALIMUMAB; ATLIZUMAB; CHEMOKINE RECEPTOR ANTAGONIST; CORTICOSTEROID; CP 481715; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ESTRADIOL 3 METHYL ETHER; ETANERCEPT; HYDROXYCHLOROQUINE; INCB 18424; INFLIXIMAB; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PROTEIN KINASE SYK INHIBITOR; R 788; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BACTERIAL INFECTION; CARTILAGE DEGENERATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; DRUG SCREENING; DRUG WITHDRAWAL; FIBROBLAST; HISTOPLASMOSIS; HUMAN; INCIDENCE; LEUKOCYTE ACTIVATION; LEUKOCYTE MOTILITY; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MYCOSIS; OSTEOLYSIS; PANNUS; PATHOLOGY; RHEUMATOID ARTHRITIS; SYNOVIUM; UNSPECIFIED SIDE EFFECT;

EID: 55349131682     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Yelin, E et al. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum 56:1397-1407, 2007.
2. Saag, KG et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762-784, 2008.
3. Strand, V, Kimberly, R, Isaacs, JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6:75-92, 2007.
4. Lainer-Carr, D, Brahn, E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 3:434-442, 2007.